Diabetes Mellitus News and Research

RSS
Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
ASN Annual Meeting to highlight six late-breaking clinical trials on nephrology

ASN Annual Meeting to highlight six late-breaking clinical trials on nephrology

Reata to present bardoxolone methyl Phase 2b clinical trial data for CKD, type 2 diabetes at ASN Conference

Reata to present bardoxolone methyl Phase 2b clinical trial data for CKD, type 2 diabetes at ASN Conference

Food insecurity may cause problem for diabetic patients living on fixed incomes

Food insecurity may cause problem for diabetic patients living on fixed incomes

Arena and Eisai report positive results from lorcaserin BLOOM-DM trial in obese, overweight diabetics

Arena and Eisai report positive results from lorcaserin BLOOM-DM trial in obese, overweight diabetics

Arena third quarter net loss increases to $36.3 million

Arena third quarter net loss increases to $36.3 million

Endocrine Society unveils new guideline on endocrine and nutritional management of post-bariatric surgery patients

Endocrine Society unveils new guideline on endocrine and nutritional management of post-bariatric surgery patients

SYMBICORT improves lung function in African American asthma patients compared to budesonide alone

SYMBICORT improves lung function in African American asthma patients compared to budesonide alone

Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study

Tolerx establishes Scientific Advisory Board to advance type 1 diabetes study

VA begins distributing disability benefits to Vietnam Veterans exposed to Agent Orange

VA begins distributing disability benefits to Vietnam Veterans exposed to Agent Orange

Biodel receives FDA CRL for Linjeta NDA

Biodel receives FDA CRL for Linjeta NDA

ChemoCentryx reports one-year study results of Traficet-EN in Crohn's disease patients

ChemoCentryx reports one-year study results of Traficet-EN in Crohn's disease patients

Health Canada approves PRADAX anticoagulant for stroke prevention in AF patients

Health Canada approves PRADAX anticoagulant for stroke prevention in AF patients

Diabetes threatens the eyesight of many unsuspecting Americans

Diabetes threatens the eyesight of many unsuspecting Americans

CYP2C19 gene variant can increase risk of cardiovascular events in patients treated with clopidogrel

CYP2C19 gene variant can increase risk of cardiovascular events in patients treated with clopidogrel

Arena's NDA receives Complete Response Letter for lorcaserin

Arena's NDA receives Complete Response Letter for lorcaserin

Diabetes on the rise in Scotland

Diabetes on the rise in Scotland

FDA issues complete response letter for BYDUREON NDA

FDA issues complete response letter for BYDUREON NDA

Study shows impaired insulin sensitivity may serve as mediator between obesity and cognitive decline

Study shows impaired insulin sensitivity may serve as mediator between obesity and cognitive decline

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

Pradaxa capsules receive FDA approval for reducing stroke and systemic embolism risk in AFib patients

Type 2 diabetes and insulin use associated with CRC risk in men, but not women

Type 2 diabetes and insulin use associated with CRC risk in men, but not women

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.